Pharm, Bio Tech Companies Ask High Court To Decide AIA’s Institution Of Inter Partes Review
WASHINGTON, D.C. — Pharmaceutical and biotechnology companies and a biotechnology trade association in an amicus curiae brief filed Oct. 24 argue in support of the U.S. Supreme Court granting review on...To view the full article, register now.
Already a subscriber? Click here to view full article